The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: A meta-analysis

This publication has 74 references indexed in Scilit:

• Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
  Annals of Oncology, 2006
• Where next for gefitinib in patients with lung cancer?
  The Lancet Oncology, 2006
• A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer
  Current Medical Research and Opinion, 2006
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  The Lancet, 2005
• Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving Gefitinib
  The Cancer Journal, 2005
• Patients Preferences in Chemotherapy for Advanced Non-small-cell Lung Cancer
  Internal Medicine, 2005
• Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2003
• Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2002
• Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews
  BMJ, 1998
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
  BMJ, 1995